GlassScriptPhysician profile
Jeffrey B Stout
NPI 1063528198
$4,580.32
in general payments reported to CMS, 2019-2025
29 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,696 · 2020: $375 · 2021: $1,189 · 2022: $1,036 · 2023: $18.89 · 2024: $126 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $284.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $823.74 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $542.72 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $444.34 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $366.69 | 2019-2022 | |
| Medtronic, INC. | $341.15 | 2021-2025 | Symplicity G3, Onyx Frontier, Ffrangio |
| Amgen INC. | $232.06 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $187.36 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $181.70 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.31 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $147.03 | 2019-2021 | |
| Astellas Pharma US INC | $146.15 | 2019-2020 | |
| Amarin Pharma, INC. | $140.32 | 2019-2021 | |
| Pfizer INC. | $130.32 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $108.46 | 2019 | |
| Abiomed | $107.10 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $93.38 | 2019-2020 | |
| Gilead Sciences, INC. | $61.90 | 2019 | |
| Boston Scientific Corporation | $55.60 | 2019-2024 | |
| Chiesi USA, INC. | $46.66 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $39.21 | 2019-2021 | |
| Portola Pharmaceuticals, LLC | $38.86 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $31.71 | 2022 | |
| Novo Nordisk INC | $31.69 | 2021-2022 | |
| Bardy Diagnostics, INC. | $30.00 | 2021 | |
| Esperion Therapeutics, INC. | $29.95 | 2021-2022 | |
| Daiichi Sankyo INC. | $17.10 | 2019 | |
| Philips North America LLC | $17.00 | 2022 | |
| Atricure, INC. | $12.92 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Stout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.